Clinical TrialJun 29, 2026, 05:12 PM
Helus Pharma Raises $50M; HLP003 Phase 3 88% Enrolled
AI Summary
Helus Pharma reported its fiscal year 2026 financial results and significant business highlights, including the successful closing of a $50 million underwritten offering. The company's HLP003 Phase 3 APPROACH study for Major Depressive Disorder has surpassed 88% enrollment and is on track for topline data in Q4 2026. Additionally, positive Phase 2 data for HLP004 in Generalized Anxiety Disorder was reported, and the company strengthened its scientific and medical leadership team. While the company reported a net loss of $148.0 million for fiscal year 2026, it ended the period with $157.3 million in cash.
Key Highlights
- Closed $50 million underwritten offering to bolster balance sheet.
- HLP003 Phase 3 APPROACH study surpassed 88% enrollment, on track for Q4 2026 data.
- HLP003 Phase 2 data showed 100% response and 71% remission at 12 months.
- HLP004 Phase 2 in GAD showed ~10-point HAM-A improvement from baseline.
- Cash totaled $157.3 million as of March 31, 2026.
- Fiscal year 2026 net loss was $148.0 million, compared to $81.6 million last year.
- Fiscal year 2026 cash-based operating expenses were $131.7 million.
- Strengthened scientific and medical leadership with globally recognized experts.
Price Impact
More from HELP